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Background: HUPRA syndrome is a rare mitochondrial disease characterized by hyperuricemia, pulmonary
hypertension, renal failure in infancy and alkalosis. This syndrome was previously described in three patients with a
homozygous mutation c.1169A > G (p.D390G) in SARS2, encoding the mitochondrial seryl-tRNA synthetase.
Case presentation: Here we report the clinical and genetic findings in a girl and her brother. Both patients were
clinically diagnosed with the HUPRA syndrome. Analysis of the pedigree identified a new homozygous mutation
c.1205G > A (p.R402H) in SARS2 gene. This mutation is very rare in the population and it is located at the C-terminal
globular domain of the homodimeric enzyme very close to p.D390G.
Conclusion: Several data support that p.R402H mutation in SARS2 is a new cause of HUPRA syndrome.
Keywords: Mitochondrial DNA, Mitochondrial disease, HUPRA syndrome, SARS2, Mitochondrial respiratory chainBackground
Mitochondria are cellular organelles that produce most of
the energy that cells use for their functions and survival
[1]. Their biogenesis and function is under the genetic
control of mitochondrial DNA (mtDNA) and nuclear
DNA. Therefore mitochondrial disorders can be origi-
nated from mutations in either of the genomes [2]. These
disorders represent one of the most common groups of
inborn errors of metabolism, with an estimated prevalence
of 1 in 5000 births [3]. The kidneys are commonly affected
in mitochondrial disease [4,5] because they are aerobic or-
gans with high energy requirements [6].
We report the case of a girl and her brother who
presented multiorgan disease, including hyperuricemia, pul-
monary hypertension, renal failure, and alkalosis (HUPRA
syndrome) (OMIM #613845) [7]. The sequencing of SARS2* Correspondence: fmartinez@h12o.es
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p.R402H) as a potential cause of the syndrome.Case presentation
Patient II-1
The patient was a girl born at 37 weeks of gestation of an
uneventful pregnancy and delivery. She was the first child
of non-consanguineous Spanish parents. At 15 months
she was referred to our department because of refractory
anemia since the age of 5 months, progressive renal failure
with hyperuricemia since the age of 11 months, and
metabolic hypochloremic alkalosis despite renal failure.
Physical examination was normal except for pallor and
mild hypotonia with motor delay. Her weight was
8.250 kg (percentile 11.5 using WHO reference), her
height 76.0 cm (percentile 30.8) and her cranial perim-
eter 46 cm (percentile 61.8). Blood test revealed a
normocytic normochromic anemia (Hb 8.4 g/dL (>12),
VCM 75 fL (70–115), HCM 27 pg (23–35), with nor-
mal leucocytes, thrombocytes and reticulocytes), meta-
bolic hypochloremic alkalosis (pH 7.51 (7.35-7.45),
pCO2 35 mmHg (27–40), HCO3
- 29.3 mmol/L (16–24), Cl-
85 mmol/L (95–106)), renal failure with disproportionatelytd. This is an Open Access article distributed under the terms of the Creative
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0.5), urea, 159 mg/dL (20–48), estimated creatinine clear-
ance of 42 mL/min/1.73 m2 (>60)) and hyperuricemia
(uric acid 11 mg/dL (2.2–7)). Urinalysis displayed a specific
gravity of 1.015, pH 5.0, absence of proteinuria and normal
cellular sediment. Abdominal ultrasound showed nor-
mal kidneys. Her bone marrow aspiration was normal
and she had neither ringed sideroblasts nor vacuolization
of hematopoietic precursors. Renal and muscle biopsies
were performed at the age of 24 months. Renal histology
showed normal glomeruli, interstitial fibrosis and tubular
atrophy with vacuoles in proximal tubular epithelial cells.
Electron microscopy revealed enlarged mitochondria in
the cytoplasm of epithelial cells of the proximal tubules.
Muscle biopsy demonstrated variations in fiber size, con-
sistent with type 2 fiber atrophy. Cytochrome C oxidase
(COX) and succinate dehydrogenase (SDH) histochemis-
try were normal. Electron microscopy study of the
muscle was normal. Enzymatic activities of mitochon-
drial respiratory chain in skeletal muscle were normal
(Table 1). Deletions of mtDNA were excluded in muscle
sample. In additional studies the pancreatic function and
the metabolic work up lactic acid, pyruvic acid, amino
acids and acylcarnitines were also normal.
In the following months the child required repeated
blood transfusions in spite of having received erythropoi-
etin treatment. She presented failure to thrive, hyperten-
sion and progressive renal failure. Her overall clinical
condition gradually deteriorated and she died at 26 months
of multiorgan failure. In the necropsy the only relevant
finding was hypertrophic cardiomyopathy.
Patient II-2
The patient was the younger brother of patient II-1. He
was born at 36 weeks of gestational age and had an un-
eventful neonatal period. At 2 months a normocytic
normochromic anemia was found with levels of Hb of
7.6 g/dL, VCM 83 fL, HCM 28 pg, which required re-
peated blood transfusions since 9 months. Bone marrow
was normal even on electron microscopy. At 3 months,Table 1 Mitochondrial respiratory chain activities in patients
Skeletal muscle
Enzyme II-1 II-2
Citrate synthase (CS)a 455 298
Complex Ib 14.8 19.5
Complex IIb 14.0 11.0
Complex IIIb 73.7 34.8
Complex IVb 53.6 43.8
aIn SA (SA is specific activity: nmol × min-1 × mg protein-1).
bIn (SA of Complex / SA of Citrate Synthase) × 100.
cSkeletal muscle from controls: N = 14.
dFibroblasts from controls: N = 6.
Bold data indicate that they are below the normal range.a hyperuricemia was found with uric acid levels of
6.6 mg/dL which increased to 9.4 mg/dL at the age of
9 months. The fractional excretion of uric acid (FeUA)
was constantly low with values of 2-3% (>7%). As a result
of failure to thrive since the age of 7 months, continuous
nasogastric night feeding and nutritional supplements
were administered at the age of 12 months. At 7 months
he had hyponatremia with an increased fractional excre-
tion of sodium, and elevated creatinine (0.96 mg/dL) dur-
ing a respiratory infection. Similar to his older sister, urea
levels were always disproportionately higher than creatin-
ine values and hypochloremic alkalosis was present des-
pite renal insufficiency. Serum magnesium levels were
1.7 mg/dL (1.5-2.3). Abdominal ultrasound showed nor-
mal kidneys. Moreover, lactic acid, amino acids and
acylcarnitines in plasma, and organic acids in urine were
normal. At 15 months he had normal social and cognitive
development with a mild motor delay, his weight was
7.860 kg (percentile 1.8 using WHO reference), his height
71.5 cm (percentile 0.1) and his cranial perimeter 44 cm
(percentile 1.8). Muscle biopsy was performed and hist-
ology, histochemistry and enzymatic studies of respiratory
chain were normal (Table 1). Mitochondrial DNA dele-
tions, depletion and frequent mutations were excluded.
Other nuclear genes were sequenced with normal results
(HNF1, UMOD, CoQ2 and PDSS2). A catheter was placed
and ambulatory peritoneal dialysis was started due to cre-
atinine values of 6.3 mg/dL. A renal biopsy was performed
at 17 months showing interstitial fibrosis and unspecific
tubular damage with normal glomeruli and vascular el-
ements by optic microscopy. Giant and abnormal
mitochondria were observed by electron microscopy
(Figure 1). Enzyme analysis of respiratory chain com-
plexes in cultured fibroblasts from a skin biopsy at
17 months revealed mild reduced activity of complexes
I and IV (Table 1).
At 16 months, severe pulmonary hypertension and
right ventricular hypertrophy were diagnosed by echo-
cardiography. In the hemodynamic study, pressures of
pulmonary arteries were at the same level as systemicwith HUPRA syndrome
Fibroblasts
C (mean ± SD)c II-2 C (mean ± SD)d
550 ± 350 76 87 ± 13
15.9 ± 5.9 13.8 19.5 ± 3.9
12.5 ± 8.0 41.8 39.7 ± 2.5
68.8 ± 37.8 63.6 63.1 ± 6.5
66.5 ± 36.5 74.8 86.3 ± 4.2
Figure 1 Electron micrograph of a kidney tubule. Abnormal
enlarged mitochondria in a portion of the tubular epithelial cells
obtained from patient II-2. Normal mitochondrion is marked with a
thin arrow and a giant mitochondrion with a wide arrow.
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ministration. Treatment with sildenafil and bosentan
showed a partial response. At 21 months he was hospital-
ized for pneumonia and died of pulmonary hemorrhage,
refractory pulmonary hypertension and cardiac failure.
Biochemical studies
Both patients with HUPRA syndrome were studied for
OXPHOS deficiencies in skeletal muscle homogenate
[8], and the patient II-2 also in skin fibroblasts [9]. These
two methodologies are slightly different being the meth-
odology used in fibroblasts more sensitive and reprodu-
cible. The activities of respiratory chain complexes in
skeletal muscle homogenate of both patients were nor-
mal (Table 1). However, the patient II-2 showed a mild
deficiency of complex I and complex IV activities in cul-
tured skin fibroblasts (Table 1), with residual activities be-
ing 71% and 87% of the mean control values (less than
one standard deviation (1SD) away from the mean value).
SARS2 sequencing
Direct DNA sequencing by Sanger method of all the
exons and the adjacent exon-intron boundaries of SARS2
gene [10] was carried out in patient II-2. One homozygous
mutation was found (c.1205G >A) resulting in p.R402H.
The same missense mutation in a homozygous fashion
was detected in patient II-1. And as expected, the parents
(I-1 and I-2,) presented the mutation in heterozygosity
(Figure 2A and B). The aminoacid change affects ahighly conserved residue (Figure 2C) and the scores
for pathogenicity obtained by in-silico analysis were
“damaging” for SIFT [11] and “probably damaging” for
PolyPhen-2 [12] software.
Conclusions
Renal involvement is frequently observed in mitochon-
drial diseases [4,5], and therefore mitochondrial dysfunc-
tion should be considered in the differential diagnosis
for unexplained renal disease in infancy [7,13]. We have
studied two related infants (sister (patient II-1) and
brother (patient II-2)) who presented failure to thrive,
anemia, metabolic hypochloremic alkalosis, pulmonary
hypertension and progressive renal failure with hyperuri-
cemia. They also showed interstitial fibrosis, tubular
damage and abnormal mitochondria in kidney. Add-
itionally, one of them also showed a mild deficiency of
the mitochondrial respiratory chain in fibroblasts (Table 1).
The patients were comprehensively investigated for com-
mon etiologies of anemia, uric acid metabolism and mito-
chondrial metabolism, including sequencing of several
genes (HNF1, UMOD, CoQ2, PDSS2 and partially the
mtDNA) but no underlying cause was identified. The
only reported patients with similar clinical characteris-
tics (3 patients from 2 unrelated Palestinian families
from the same village) were diagnosed with the HUPRA
syndrome [7] and therefore the patients II-1 and II-2 were
clinically diagnosed with this syndrome. The genetic basis
of HUPRA syndrome in Palestinian patients was a homo-
zygous mutation (c.1169A >G p.D390G) in the SARS2
gene (RefSeq NG_031865.1) [10], which encodes mito-
chondrial seryl‐tRNA synthetase [7]. The patients II-1 and
II-2, unlike the Palestinian patients, had a more severe
anemia, a milder developmental delay, normal levels of
blood lactate, and normal COX histochemistry and mito-
chondrial respiratory chain activities in muscle. However,
normal respiratory chain activities and morphology in
muscle does not rule out the diagnosis of mitochondrial
dysfunction. Thus, similar situations have been described
before where respiratory chain activities in fibroblasts
showed deficiencies while respiratory chain activities and
histochemical analysis in muscle were normal [14]. On the
other hand, lactic acid elevation in blood is an important,
although non-specific and non-sensitive, marker of mito-
chondrial disease. Many patients with mitochondrial dis-
eases consistently have normal lactic acid levels, even it
has been described pathogenic mutations in DARS2 where
elevated lactate was only observed in the affected tissue
(white matter) and not in blood or cerebrospinal fluid
[15]. Additionally, from a cohort of 113 pediatric patients
with mitochondrial disease, a significant respiratory chain
defect was found in 71% of the patients, focal absence of
COX activity was found only in 13% of patients and eleva-
tion of plasma lactic acid in 60% of them [16]. Thus,
Figure 2 Validation and segregation of c.1205G > A (p.R402H) mutation in SARS2. (A) Family pedigree. (B) Electropherograms showing
Sanger sequence validation of the SARS2 c.1205G > A (p.R402H) mutation. (C) Multiple sequence alignment of SARS2 protein region surrounding
the novel R402H mutation (blue) in various species. The position of D390G mutation is also indicated (red). (D) Spatial localization of R402 (blue)
and D390 (red) is shown in the model of 3D structure of SARS2 protein (PDB code 1WLE). R402 is mutated in patients II-1 and II-2 and D390 is
mutated in previously described patients with HUPRA syndrome.
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patients can be challenging due to it can be accompanied
by normal muscle morphology, normal plasma lactate,
normal mitochondrial enzymes in skeletal muscle, normal
mtDNA mutation screening, and a non-classical clinical
presentation.The description of HUPRA syndrome and it genetic
origin due to a mutation in SARS2 gene [7] prompted us
to sequence this gene in the patients II-1 and II-2. The
sequencing identified a very rare missense mutation in
homozygous (c.1205G > A) in both patients that changes a
conserved arginine to histidine (p.R402H). The mutation
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population (13006 alleles), and the frequency of homozy-
gous is 0 (in 6503 chromosomes). It has been described
only twice in heterozygous in the Exome Sequencing
Project (ESP) (https://esp.gs.washington.edu/drupal/).
Furthermore, the mutation was predicted to have dele-
terious effect in the protein by analysis with SIFT [11]
and PolyPhen-2 [12] software. It is located in one of
the most conserved region of SARS2 and the aminoacid is
conserved from Homo sapiens to Arabidopsis thaliana
(Figure 2C). The mutation segregates with the disease in
this family (Figure 2A and B): the same mutation was
detected in patients II-1 and II-2 with identical phenotype,
and the parents (I-1 and I-2,) were carriers of the
mutation.
SARS2 is a homodimeric enzyme whose active site
C-terminal globular domain is built around an eight
antiparallel β-sheet, encompassed by three helical bun-
dles. The aminoacids D390 and R402 are positioned at
the C-terminal globular domain, D390 is in the second
and R402 in the third β-strands surrounding an α-helix
and a β-turn [17]. In the three-dimensional structure
of the protein, both residues are very close (2.8 Å)
(Figure 2D) [18], which could explain why mutations in
these residues give rise to similar clinical phenotypes.
Recently, mutations in genes encoding mitochondrial
aminoacyl-tRNA synthetases (mtARSs) have emerged as a
new cause of human disease, resulting in surprisingly
tissue-specific phenotypes, although they are all expected
to impair mitochondrial protein synthesis and thus affect
the OXPHOS system. However, the molecular mecha-
nisms behind the selective tissue involvement are not cur-
rently understood. Several possibilities have been pointed
out to explain the tissue-specificity phenotype of mtARS
mutation [19]: (i) the remaining residual activity of mtARS
is sufficient to maintain mitochondrial translation in most
cell types but not in the specific tissues; (ii) tissue-specific
differences in mitochondrial chaperone activities may play
a role in determining the stability of some mutants; (iii)
tissue-specific levels of particular uncharged tRNAs and
amino acids; and (iv) mtARS could also have additional
functions that are indispensable in specific cell types or
developmental stages.
The principal affected tissue in HUPRA syndrome by
SARS2 mutations is the kidney. Mutations in SARS2
resulting in decreased aminoacylation of one tRNA
isoacceptor (tRNASerAGY or tRNA
Ser
UCN) by the serine
amino acid are expected to adversely affect mitochon-
drial translation systems and lead to derangements in
the synthesis of mitochondrial proteins and conse-
quently in energy supply. Reduced energy production
may account for impaired tubular function, which is
known to be especially vulnerable to mitochondrial dys-
function since it has very high energy requirements [6].In conclusion, there are several findings that support
the pathogenic role of R402H change: (i) the mutation is
very rare in the population; (ii) the substitution is pre-
dicted to have deleterious effect in the protein; (iii) the
aminoacid residue is highly conserved (Figure 2C); (iv)
the mutation segregates with the disease (Figure 2A); (v)
the patient fibroblasts have a combined deficiency in com-
plexes of the mitochondrial respiratory chain (Table 1) as
expected for defects in a gene involved in mitochondrial
protein synthesis; and (vi) the mutation is located close to
the only described mutation in SARS2 associated with
HUPRA syndrome (Figure 2D) [7]. Finally, we consider
that the SARS2 gene must be the first line of investigation
when the HUPRA phenotype is present.
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